ABSTRACT
Cervical cancer is one of the most common gynecological cancer across the world and accurate diagnosis is crucial for optimal therapy management of patients. F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computerized tomography (CT) has a significant role in diagnosis of cervical cancer, which was declared in recent guidelines. The therapy management of newly diagnosed cervical cancer is planned according to the revised International Federation of Gynecology and Obstetrics 2018 classification by using clinical, histopathological and diagnostic findings. Local therapies are sufficient for early stage of cervical cancer, while systemic therapies are needed in advanced disease. F-18 FDG PET/CT has an advantage by defining metabolic characteristics of lesions which provides accurate diagnosis in detection of nodal-distant metastases, local recurrence and therapy response assessment of cervical cancer. Besides, F-18 FDG PET/CT has prognostic and predictive role which may impact the management of patients. F-18 FDG PET/magnetic resonance (MR) has also made contribution in diagnosis of cervical cancer by using the metabolic and anatomic findings of both modalities. Beyond F-18 FDG, several PET radiopharmaceuticals have also been used in selected patients with different indications. Recently, artificial intelligence implications are used to improve diagnostic power of F-18 FDG PET/CT with promising results. In the present review, the role of F-18 FDG PET/CT in cervical cancer is discussed.
References
1
Lin S, Gao K, Gu S, et al. Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years. Cancer. 2021;127:4030-4039.
2
Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: cancer today. International Agency for Research on Cancer. Lyon, France. 2020.
3
Reid R, Stanhope CR, Herschman BR, et al. Genital warts and cervical cancer. I. Evidence of an association between subclinical papillomavirus infection and cervical malignancy. Cancer 1982;50:377-387.
4
Moch H. Female genital tumours: WHO Classification of Tumours, Volume 4. WHO Classification of Tumours. 2020;4.
5
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
6
Bethesda M. SEER Cancer Stat Facts: Cervical Cancer. National Cancer Institute. 2019.
7
Marth C, Landoni F, Mahner S, et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(suppl 4):iv72-iv83.
8
Chuang LT, Temin S, Camacho R, et al. Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline. J Glob Oncol 2016;2:311-340.
9
Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet 2018;143 Suppl 2:22-36.
10
Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Magnetic resonance imaging for detection of parametrial invasion in cervical cancer: An updated systematic review and meta-analysis of the literature between 2012 and 2016. Eur Radiol 2018;28:530-541.
11
Balcacer P, Shergill A, Litkouhi B. MRI of cervical cancer with a surgical perspective: staging, prognostic implications and pitfalls. Abdom Radiol (NY) 2019;44:2557-2571.
12
Koh WJ, Abu-Rustum NR, Bean S, et al. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019;17:64-84.
13
Cibula D, Pötter R, Planchamp F, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer. Virchows Arch 2018;472:919-936.
14
Benedetti-Panici P, Maneschi F, Scambia G, et al. Lymphatic spread of cervical cancer: an anatomical and pathological study based on 225 radical hysterectomies with systematic pelvic and aortic lymphadenectomy. Gynecol Oncol 1996;62:19-24.
15
Carlson V, Delclos L, Fletcher GH. Distant metastases in squamous-cell carcinoma of the uterine cervix. Radiology 1967;88:961-966.
16
Byun JM, Kim YN, Jeong DH, Kim KT, Sung MS, Lee KB. Three-dimensional transvaginal ultrasonography for locally advanced cervical cancer. Int J Gynecol Cancer 2013;23:1459-1464.
17
Arribas S, Alcázar JL, Arraiza M, Benito A, Minguez JA, Jurado M. Three-Dimensional Transvaginal Sonography and Magnetic Resonance Imaging for Local Staging of Cervical Cancer: An Agreement Study. J Ultrasound Med 2016;35:867-873.
18
Fischerova D, Cibula D, Stenhova H, et al. Transrectal ultrasound and magnetic resonance imaging in staging of early cervical cancer. Int J Gynecol Cancer 2008;18:766-772.
19
Sala E, Wakely S, Senior E, Lomas D. MRI of malignant neoplasms of the uterine corpus and cervix. AJR Am J Roentgenol 2007;188:1577-1587.
20
Dappa E, Elger T, Hasenburg A, Düber C, Battista MJ, Hötker AM. The value of advanced MRI techniques in the assessment of cervical cancer: a review. Insights Imaging 2017;8:471-481.
21
Choi HJ, Ju W, Myung SK, Kim Y. Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis. Cancer Sci 2010;101:1471-1479.
22
Liu B, Gao S, Li S. A Comprehensive Comparison of CT, MRI, Positron Emission Tomography or Positron Emission Tomography/CT, and Diffusion Weighted Imaging-MRI for Detecting the Lymph Nodes Metastases in Patients with Cervical Cancer: A Meta-Analysis Based on 67 Studies. Gynecol Obstet Invest 2017;82:209-222.
23
He T, Sun J, Wu J, et al. PET-CT versus MRI in the diagnosis of lymph node metastasis of cervical cancer: A meta-analysis. Microsc Res Tech 2022;85:1791-1798.
24
Sponholtz SE, Mogensen O, Hildebrandt MG, et al. Sentinel lymph node mapping in early-stage cervical cancer - A national prospective multicenter study (SENTIREC trial). Gynecol Oncol 2021;162:546-554.
25
Leblanc E, Katdare N, Narducci F, et al. Should Systematic Infrarenal Para-aortic Dissection Be the Rule in the Pretherapeutic Staging of Primary or Recurrent Locally Advanced Cervix Cancer Patients With a Negative Preoperative Para-aortic PET Imaging? Int J Gynecol Cancer 2016;26:169-175.
26
Adam JA, van Diepen PR, Mom CH, Stoker J, van Eck-Smit BLF, Bipat S. [18F]FDG-PET or PET/CT in the evaluation of pelvic and para-aortic lymph nodes in patients with locally advanced cervical cancer: A systematic review of the literature. Gynecol Oncol 2020;159:588-596.
27
Lin A, Ma S, Dehdashti F, et al. Detection of distant metastatic disease by positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) at initial staging of cervical carcinoma. Int J Gynecol Cancer 2019;29:487-491.
28
Gee MS, Atri M, Bandos AI, Mannel RS, Gold MA, Lee SI. Identification of Distant Metastatic Disease in Uterine Cervical and Endometrial Cancers with FDG PET/CT: Analysis from the ACRIN 6671/GOG 0233 Multicenter Trial. Radiology 2018;287:176-184.
29
Fleming S, Cooper RA, Swift SE, et al. Clinical impact of FDG PET-CT on the management of patients with locally advanced cervical carcinoma. Clin Radiol 2014;69:1235-1243.
30
Salem A, Salem AF, Al-Ibraheem A, Lataifeh I, Almousa A, Jaradat I. Evidence for the use PET for radiation therapy planning in patients with cervical cancer: a systematic review. Hematol Oncol Stem Cell Ther 2011;4:173-181.
31
Li H, Wu X, Cheng X. Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol 2016;27:e43.
32
Perez CA, Grigsby PW, Camel HM, Galakatos AE, Mutch D, Lockett MA. Irradiation alone or combined with surgery in stage IB, IIA, and IIB carcinoma of uterine cervix: update of a nonrandomized comparison. Int J Radiat Oncol Biol Phys 1995;31:703-716.
33
Manganaro L, Lakhman Y, Bharwani N, et al. Staging, recurrence and follow-up of uterine cervical cancer using MRI: Updated Guidelines of the European Society of Urogenital Radiology after revised FIGO staging 2018. Eur Radiol 2021;31:7802-7816.
34
Chu Y, Zheng A, Wang F, et al. Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis. Nucl Med Commun 2014;35:144-150.
35
Chong A, Ha JM, Jeong SY, et al. Clinical Usefulness of (18)F-FDG PET/CT in the Detection of Early Recurrence in Treated Cervical Cancer Patients with Unexplained Elevation of Serum Tumor Markers. Chonnam Med J 2013;49:20-6.
36
Perrone AM, Dondi G, Coe M, et al. Predictive Role of MRI and 18F FDG PET Response to Concurrent Chemoradiation in T2b Cervical Cancer on Clinical Outcome: A Retrospective Single Center Study. Cancers (Basel) 2020;12:659.
37
Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Metabolic response on post-therapy FDG-PET predicts patterns of failure after radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 2012;83:185-190.
38
Scarsbrook A, Vaidyanathan S, Chowdhury F, Swift S, Cooper R, Patel C. Efficacy of qualitative response assessment interpretation criteria at 18F-FDG PET-CT for predicting outcome in locally advanced cervical carcinoma treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging 2017;44:581-588.
39
Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 2007;110:1738-1744.
40
Han S, Kim H, Kim YJ, Suh CH, Woo S. Prognostic Value of Volume-Based Metabolic Parameters of 18F-FDG PET/CT in Uterine Cervical Cancer: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol 2018;211:1112-1121.
41
Kidd EA, Siegel BA, Dehdashti F, et al. Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol 2010;28:2108-2113.
42
Lin Y, Lin WY, Liang JA, et al. Opportunities for 2-[(18)F] fluoro-2-deoxy-D-glucose PET/CT in cervical-vaginal neuroendocrine carcinoma: case series and literature review. Korean J Radiol 2012;13:760-770.
43
Elsherif S, Odisio EGLC, Faria S, et al. Imaging and staging of neuroendocrine cervical cancer. Abdom Radiol (NY) 2018;43:3468-3478.
44
Damian A, Lago G, Rossi S, Alonso O, Engler H. Early Detection of Bone Metastasis in Small Cell Neuroendocrine Carcinoma of the Cervix by 68Ga-DOTATATE PET/CT Imaging. Clin Nucl Med 2017;42:216-217.
45
Cho LP, Kim CK, Viswanathan AN. Pilot study assessing (18)F-fluorothymidine PET/CT in cervical and vaginal cancers before and after external beam radiation. Gynecol Oncol Rep 2015;14:34-37.
46
Wyss JC, Carmona R, Karunamuni RA, Pritz J, Hoh CK, Mell LK. [(18)F]Fluoro-2-deoxy-2-d-glucose versus 3'-deoxy-3'-[(18)F]fluorothymidine for defining hematopoietically active pelvic bone marrow in gynecologic patients. Radiother Oncol 2016;118:72-78.
47
Georg P, Andrzejewski P, Baltzer P, et al. Changes in Tumor Biology During Chemoradiation of Cervix Cancer Assessed by Multiparametric MRI and Hypoxia PET. Mol Imaging Biol 2018;20:160-169.
48
Dendl K, Koerber SA, Finck R, et al. 68Ga-FAPI-PET/CT in patients with various gynecological malignancies. Eur J Nucl Med Mol Imaging 2021;48:4089-4100.
49
Ferdinandus J, Costa PF, Kessler L, et al. Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients. J Nucl Med 2022;63:727-734.
50
Nie J, Zhang J, Gao J, et al. Diagnostic role of 18F-FDG PET/MRI in patients with gynecological malignancies of the pelvis: A systematic review and meta-analysis. PLoS One 2017;12:e0175401.
51
Schwartz M, Gavane SC, Bou-Ayache J, et al. Feasibility and diagnostic performance of hybrid PET/MRI compared with PET/CT for gynecological malignancies: a prospective pilot study. Abdom Radiol (NY) 2018;43:3462-3467.
52
Gong J, Liu H, Bao Z, Bian L, Li X, Meng Y. Relative clinical utility of simultaneous 18F-fluorodeoxyglucose PET/MRI and PET/CT for preoperative cervical cancer diagnosis. J Int Med Res 2021;49:3000605211019190.
53
Grueneisen J, Schaarschmidt BM, Heubner M, et al. Implementation of FAST-PET/MRI for whole-body staging of female patients with recurrent pelvic malignancies: A comparison to PET/CT. Eur J Radiol 2015;84:2097-2102.
54
Ming Y, Dong X, Zhao J, Chen Z, Wang H, Wu N. Deep learning-based multimodal image analysis for cervical cancer detection. Methods 2022;205:46-52.
55
Shen WC, Chen SW, Wu KC, et al. Prediction of local relapse and distant metastasis in patients with definitive chemoradiotherapy-treated cervical cancer by deep learning from [18F]-fluorodeoxyglucose positron emission tomography/computed tomography. Eur Radiol 2019;29:6741-6749.